Key result
Apixaban shortens thrombosis test lysis time by ~320 seconds in non-valvular atrial fibrillation.
Why the study?
Endogenous fibrinolysis strongly relates to improved functional outcome after ischaemic stroke, but the impact of oral anticoagulants on endogenous fibrinolysis is unknown.
Does apixaban enhance endogenous fibrinolysis compared with pre-treatment baseline and compared with warfarin or aspirin in patients with non-valvular atrial fibrillation?
Cohort (n=200)
Anti-FXa levels were assessed by an independent investigator blinded to GTT and TEG results
Does apixaban enhance endogenous fibrinolysis compared with pre-treatment baseline and compared with warfarin or aspirin in patients with non-valvular atrial fibrillation?
This study provides the first evidence that an oral medication, apixaban, enhances endogenous fibrinolysis in patients with non-valvular atrial fibrillation, particularly among those with impaired pre-treatment fibrinolysis, exhibiting a more favourable fibrinolytic profile than warfarin or aspirin.
Answers are grounded in this paper and cite their sources.
Apixaban may enhance fibrinolysis in non-valvular AF; hypothesis-generating and requires randomized confirmation before practice change.
AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome. The impact of oral anticoagulants on endogenous fibrinolysis is unknown. Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis in non-valvular atrial fibrillation (NVAF). METHODS AND RESULTS: In a prospective cross-sectional analysis, we compared endogenous fibrinolysis in NVAF patients (n = 180) taking aspirin, warfarin, or apixaban. In a prospective longitudinal study, patients were tested before and after apixaban (n = 80). Endogenous fibrinolysis was assessed using the Global Thrombosis Test (GTT) and thromboelastography (TEG). Endogenous fibrinolysis [measured by GTT lysis time (LT)] was shorter on apixaban compared with warfarin or aspirin [median 1850 (IQR 1591-2300) vs. 2758 (2014-3502) vs. 2135 (1752-2463) s, P < 0.0001]. Among TEG indices, a small but significant difference in clot lysis time (CLT) was observed [apixaban 60.0 (45.0-61.0) vs. warfarin 61.0 (57.0-62.0) vs. aspirin 61.0 (59.0-61.0) min, P = 0.036]. Apixaban improved endogenous fibrinolysis measured using the GTT [LT pre-treatment 2204 (1779-2738) vs. on-treatment 1882 (1607-2374) s, P = 0.0003], but not by using TEG. Change in LT (ΔLT) with apixaban correlated with baseline LT (r = 0.77, P < 0.0001). There was weak correlation between ΔLT and ΔCLT in response to apixaban (r = 0.28, P = 0.02) and between on-apixaban LT and CLT (r = 0.25, P = 0.022). CONCLUSION: Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.
No takes yet. Share an insight, caveat, or question.
Spinthakis et al. (2019) conducted a cohort in Non-valvular atrial fibrillation (NVAF) (n=200). Apixaban vs. Pre-treatment baseline (longitudinal study, n=80) and warfarin or aspirin (cross-sectional study, n=180) was evaluated on Change in endogenous fibrinolysis measured by Global Thrombosis Test (GTT) lysis time (LT) in response to apixaban in the longitudinal study (p=0.0003). Apixaban reduced Global Thrombosis Test lysis time from a median of 2204 s pre-treatment to 1882 s on-treatment in patients with non-valvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: